Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIDUAL: Optimal Duration of Dual Antiplatelet Therapy After DES
NCT00822536Phase 4Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2009
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clopidogrel in coronary artery disease (CAD) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Composite criteria : death, non fatal myocardial infarction, non fatal stroke and severe bleeding at 3 years. Started Jan 2009; status: completed.
02
Drugs
clopidogrel
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00822536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00822536.